Clinical trials (e.g., CHRYSALIS; NCT02609776; and others) have shown acceptable toxicity and anti-tumor efficacy of Amivantamab in patients with locally advanced or metastatic NSCLC and EGFR Ex20ins mutations based on the ORR of about 40% and duration of response [126]. The gene discussed is EGFR; the disease is neoplasm.